Raymond James upgrades Casey’s General Stores stock rating on valuation
Source: Investing.com

Raymond James upgraded Casey's General Stores to Outperform with a $750 price target after its shares fell 14% following earnings, characterizing the decline as a reset in expectations rather than fundamental deterioration. Fiscal Q1 2027 EBITDA rose 17% year over year, diluted EPS of $7.37 beat the $6.68 consensus estimate, and revenue grew 24.3% to $5.68 billion. The firm cited sustained 7%-8% two-year stacked inside comparable-sales growth, healthy fuel profitability and encouraging CEFCO remodel and wing-rollout results, although investors remain concerned about near-term cash flow and capital spending.
Analysis
CASY’s post-print weakness is more likely a valuation-duration reset than an operating inflection, but the market is correctly focusing on the conversion of store-level momentum into free cash flow. The key underwriting variable is whether remodel and food-service returns remain above the company’s cost of capital while capital intensity rises; sustained high-single-digit two-year inside-sales stacks would support that outcome, whereas unit-volume deceleration would expose a premium multiple despite reported EBITDA growth.
The underappreciated competitive implication is that CASY’s prepared-food mix makes it less comparable to fuel-exposed convenience peers such as MUSA and more akin to a small-format foodservice compounder. Successful integration and remodeling of acquired locations could create a multi-year gross-margin and customer-frequency lift, while regional independents lack the scale to match loyalty, distribution, and menu innovation. Conversely, a broad-based fuel-margin normalization would matter less to the long thesis than a deterioration in food attachment rates, labor costs, or remodel paybacks.
Near term, technical mean reversion can support a rebound after a sharp one-day expectation reset, but a durable rerating requires evidence over the next one to two quarterly reports that operating cash flow and capex normalize relative to EBITDA. Consensus may be over-penalizing investment spending that is growth-oriented, but this is falsified if free-cash-flow conversion fails to improve as remodel cohorts mature or if management reduces unit-growth/return targets. RJF has no material read-through beyond a standard research-franchise benefit.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
Key Decisions for Investors
- Accumulate CASY on weakness over the next 1-4 weeks, preferably in tranches rather than chasing an oversold bounce; target a recovery toward the $750 analyst valuation over 6-12 months, with the thesis contingent on continued positive inside-sales volume and stable prepared-food margins.
- Use a 3-6 month CASY call spread rather than outright short-dated calls if implied volatility rises around the next earnings date: the expected catalyst is cash-flow/capex validation, not merely another earnings beat. Limit risk if the stock closes materially below the post-earnings low or management cuts return-on-investment expectations.
- For relative-value exposure, consider long CASY versus short MUSA only if fuel-margin concerns drive the sector lower indiscriminately. CASY should outperform if food-led same-store sales and remodel returns remain intact; exit if fuel profitability becomes the dominant earnings driver again or inside-sales trends decelerate materially.
- Monitor the next quarterly disclosures for operating cash flow, capex per remodel/acquired store, prepared-food gross margin, and inside comparable-sales volumes. A widening EBITDA-to-free-cash-flow gap beyond the planned investment period is a thesis-breaker, not a buying opportunity.
More News
- Jim Cramer's top 10 things to watch in the stock market Thursday
- ‘We worry now’: Oil tops $100, diesel hits record highs amid Iran war escalation
- Here are Thursday's biggest analyst calls: Nvidia, SpaceX, Tesla, Ferrari, Meta, Apple, AMD, Yum & more
- Stifel reiterates Biogen stock rating on immunology pipeline
- Wall Street Is Wrong About These 2 Chip Stocks
- Here's Where Wall Street Analysts See Nvidia's Share Price Going